| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MAGI1 |
| Uniprot No | Q96QZ7 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 761-859aa |
| 活性数据 | SHSTQVLPEFPPAEAQAPDQTDSSGQKKPDPFKIWAQSRSMYENRPMSPSPASGLSKGEREREINSTNFGECPIPDYQEQDIFLWRKETGFGFRILGGN |
| 分子量 | 36.63 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下为关于重组人MAGI1蛋白的参考文献概要：
1. **"Structural analysis of MAGI1 PDZ domains in complex with HPV E6 oncoproteins"**
- **作者**: Nakagawa S, et al.
- **摘要**: 研究通过重组人MAGI1蛋白的PDZ结构域与HPV病毒E6蛋白的相互作用，揭示MAGI1在HPV致癌机制中的关键作用，证实其结构域结合能力可被用于开发抗病毒靶点。
2. **"Functional characterization of MAGI1 in epithelial cell polarity maintenance"**
- **作者**: Wu Y, et al.
- **摘要**: 利用重组MAGI1蛋白进行体外实验，证明其通过调节细胞连接复合物(如紧密连接)维持上皮细胞极性，并阐明其缺陷可能导致上皮屏障功能障碍。
3. **"Recombinant MAGI1 as a scaffold protein for neuronal signaling complexes"**
- **作者**: Olsen O, et al.
- **摘要**: 研究发现重组MAGI1蛋白可促进神经元突触后致密区信号分子的组装，揭示其在神经突触可塑性和神经系统疾病中的潜在调控机制。
4. **"Interaction between MAGI1 and PTEN: implications in tumor suppression"**
- **作者**: Vasko R, et al.
- **摘要**: 通过重组蛋白互作实验，证实MAGI1通过稳定PTEN蛋白增强其抑癌活性，为癌症治疗中靶向MAGI1-PTEN信号通路提供了理论基础。
以上研究聚焦于MAGI1的结构、功能及疾病相关性，涵盖病毒致癌、细胞极性、神经信号和肿瘤抑制领域。
**Background of Recombinant Human MAGI1 Protein**
MAGI1 (Membrane-Associated Guanylate Kinase Inverted 1) is a scaffolding protein involved in cell-cell junction organization, signal transduction, and polarity regulation. Structurally, it contains multiple protein-binding domains, including PDZ, WW, and GUK domains, enabling interactions with diverse partners like receptors, adhesion molecules, and signaling proteins (e.g., β-catenin, PTEN). These interactions stabilize cellular architecture and modulate pathways such as Wnt, Hippo, and PI3K/AKT, impacting tissue development, homeostasis, and disease processes.
Dysregulation of MAGI1 is linked to pathologies, including cancer, neurological disorders, and kidney diseases. In cancer, MAGI1 often acts as a tumor suppressor by inhibiting proliferation or metastasis, while its loss or mutation correlates with poor prognosis. In neurons, MAGI1 supports synaptic stability and signaling, with disruptions implicated in neurodevelopmental conditions.
Recombinant MAGI1 protein, produced via heterologous expression systems (e.g., mammalian or insect cells), retains functional domains and post-translational modifications, enabling in vitro studies. It is vital for investigating MAGI1’s molecular roles, screening therapeutic agents targeting its interactors, or modeling diseases. Its applications span structural biology, interactome mapping, and mechanistic studies of junctional complexes or signaling networks. Research on recombinant MAGI1 continues to unveil its therapeutic potential in regenerative medicine and precision oncology.
×
